Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5‑HT3 receptor antagonist presented as an oral dosage form for systemic use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: provides prophylaxis and treatment for patients undergoing radiotherapy. - Postoperative nausea and vomiting: helps prevent and treat nausea after surgical procedures.

Common Side Effects: - Headache: mild to moderate pain often reported. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reaction (anaphylaxis): swelling, rash, breathing difficulty. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Cardiac arrhythmia: irregular heartbeat. - Stevens‑Johnson syndrome: severe skin blistering.

Before initiating therapy, consider the following precautions: - Cardiac assessment: evaluate baseline ECG in patients with known heart disease. - QT monitoring: avoid concomitant QT‑prolonging drugs. - Hepatic impairment: use with caution in moderate to severe liver dysfunction. - Hypersensitivity: discontinue if allergic reaction occurs. - Pregnancy and lactation: assess risk‑benefit ratio before use. - Store at room temperature: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Apomorphine: co‑administration can cause severe hypotension. - Other QT‑prolonging agents (e.g., quinidine, erythromycin): increase risk of cardiac arrhythmia. - Carbamazepine: induces metabolism, reducing ondansetron efficacy. - Ritonavir and other strong CYP3A4 inhibitors: raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Dexamethasone: may enhance anti‑emetic effect, monitor for additive side effects. - Other anti‑emetics (e.g., metoclopramide): assess for overlapping toxicity. - Antidepressants (e.g., SSRIs): watch for serotonin syndrome symptoms.